Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Year: 2025
Type: supplementary-materials
Abstract: p-H2AX as a pharmacodynamic biomarker for TP-0903. Spectral flow cytometry was performed to assess p-H2AX using peripheral blood collected at day 1 (i.e., baseline) and day 10, and change from screening was calculated for patients that achieved CR, patients that achieved CRh, CRi, or MLFS, and non-responders.
Authors: Eric D. Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow, Nicole Abbott, Mitch Phelps, Joshua Zeidner, Matthew C. Foster, Tara L. Lin, Maria R. Baer, Yazan F. Madanat, Tibor Kovacsovics, Robert Redner, Zeina Al-Mansour, Bhavana Bhatnagar, Mona Stefanos, Molly Martycz, Franchesca Druggan, Timothy L. Chen, Ashley O. Yocum, Uma Borate, Brian J. Druker, Amy Burd, Ross L. Levine, John C. Byrd, Sharyn D. Baker, Alice S. Mims
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4412385404